Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nino Müser"'
Autor:
Maximilian Hochmair, Angelika Terbuch, David Lang, Christian Trockenbacher, Florian Augustin, Bahil Ghanim, Dominik Maurer, Hossein Taghizadeh, Christoph Kamhuber, Robert Wurm, Jörg Lindenmann, Petra Braz, Tatjana Bundalo, Merjem Begic, Johanna Bauer, Patrick Reimann, Nino Müser, Florian Huemer, Verena Schlintl, Daniela Bianconi, Bernhard Baumgartner, Peter Schenk, Markus Rauter, Konrad Hötzenecker
Publikováno v:
Cancers, Vol 16, Iss 14, p 2586 (2024)
This was a retrospective study of the profile and initial treatments of adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018–December 2021 at 16 leading hospital institutions in Austria, excluding patients e
Externí odkaz:
https://doaj.org/article/3e588c78b2714c87bb4a690e179356da
Autor:
Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister, Maria Theresa Krauth
Publikováno v:
Cancers, Vol 13, Iss 18, p 4701 (2021)
Since the introduction of first-generation proteasome inhibitors and immunomodulatory agents, the multiple myeloma (MM) treatment landscape has undergone a remarkable development. Most recently, immunotherapeutic strategies targeting the B cell matur
Externí odkaz:
https://doaj.org/article/932fb0ebbc4846d290f19f12b9f422ae
Autor:
Simon Udovica, Nino Müser, Agnes Pechlaner, Andreas Reichinger, Christoph Aichinger, Kathrin Strasser-Weippl, Holger Rumpold, Andreas Petzer, Ewald Wöll, Wolfgang Hilbe, Ercan Müldür
Publikováno v:
memo - Magazine of European Medical Oncology. 15:153-160
Autor:
Hermine Agis, Martin Schreder, Maria Theresa Krauth, Peter Neumeister, Tina Künz, Irene Strassl, Normann Steiner, Nino Müser, Jakob Rudzki, Andreas L. Petzer, Wolfgang Willenbacher
Publikováno v:
Cancers
Cancers, Vol 13, Iss 4701, p 4701 (2021)
Cancers, Vol 13, Iss 4701, p 4701 (2021)
Simple Summary There is no doubt that immunotherapeutic approaches will change the current treatment landscape of multiple myeloma in the near future; in particular, a wave of BCMA-targeted therapies is currently entering clinical routine. Although t